Price
No data yet.
Signal Score (90d)
120Aug 17Aug 17
Revenue
$441.59M+730.06%Jun 2016Dec 2025
Quote
Day Range
$3.30 – $3.30
52-Week Range
$1.30 – $3.30
Volume
$1.8K
Market Cap
$7.21B
50-Day Avg
$1.86
200-Day Avg
$1.79
Prev Close
$3.21
Open
$3.30
Valuation & Ratios
P/E Ratio
-6.64
EPS
$-0.25
P/B Ratio
0.91
P/S Ratio
3.74
Debt/Equity
0.15
Current Ratio
1.47
Dividend Yield
+0.0%
Gross Margin
+57.7%
Returns & Efficiency
Return on Equity
-13.5%
Return on Assets
-11.0%
FCF Yield
+6.7%
EV/EBITDA
12.23
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $960.95M | $-533.62M | $-0.25 |
| 2024 | $594.49M | $2.96B | $1.40 |
| 2023 | $839.53M | $-95.48M | $-0.05 |
| 2022 | $625.70M | $-226.85M | $-0.11 |
| 2021 | $511.06M | $-358.71M | $-0.18 |
Social Signal Score
70
5d
71
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1
Earnings
Wed, Mar 24(in 7 months)
Consensus estimate $-0.01 per share
2of 5 quarters beat consensus
Typical surprise -127.0% (median, so one quarter with a near-zero estimate can't distort it)
- Sun, Mar 15$-0.23 vs $-0.03miss
- Sun, Aug 17$-0.02 vs $0.08miss
- Tue, Mar 11$1.48 vs $-0.01beat
- Fri, Aug 9$-0.08 vs $-0.01miss
- Sun, Mar 10$-0.03 vs $-0.05beat
Estimates and results for GNNSF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
GNNSFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
Genscript Biotech Corporation (GNNSF) Q2 2026 Earnings Call Transcript Genscript Biotech Corporation (GNNSF) Q2 2026 Earnings Call Transcript
View source ↗